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Summary Amplification and expression of the mdrl gene encoding P-glycoprotein have been studied in
H69/LX4 a multidrug resistant variant (MDR) of small cell lung cancer (SCLC) cell line NCI-H69. Recently
a second independently derived MDR variant of this cell line designated H69/AR was found by others not to
show amplification, rearrangement or over-expression of the mdrl gene. The present study reports that in
marked contrast to H69/AR, H69/LX4 shows amplification and expression of the P-glycoprotein gene and
raises the possibility that P-glycoprotein hyperexpression may be a clinically relevant component of MDR in
some SCLC tumours.
Resistance of tumours to multiple drugs is a major problem
in cancer treatment. Studies using in vitro derived multidrug-
resistant (MDR) cell lines have shown that MDR is often
associated with over-production of two groups of proteins:
the P-glycoproteins (for review see Riordan & Ling, 1985)
which have drug-binding properties (Safa et al., 1986) and
are thought to function as a membrane anchored efflux
pump for multiple drugs (Willingham et al., 1986); and
sorcin/CP22 (Meyers et al., 1985; Meyers & Biedler, 1981;
Koch et al., 1986; Martinnson et al., 1985; Shen et al.,
1986a; Van der Bliek et al., 1986a), a small cytosolic
calcium-binding protein. Considerable evidence supports the
hypothesis that it is P-glycoprotein that is responsible for
MDR in almost all cell lines examined (Debenham et al.,
1982; Gros et al., 1986; Kartner et al., 1983; Riordan et al.,
1985; Robertson et al., 1984; Scotto et al., 1986; Shen et al.,
1986b; Van der Bliek et al., 1986b).
In an effort to elucidate mechanisms of MDR in human
small cell lung cancer (SCLC), multidrug resistant variants
(MDR) of human SCLC cell line NCI-H69, have recently
been derived following cell culture in increasing doses of
adriamycin (ADM) (Twentyman et al., 1986; Mirksi et al.,
1987). Surprisingly, the MDR variant H69/AR (Mirski et al.,
1987) does not show amplification, rearrangement or over-
expression of the P-glycoprotein gene (Trent et al., 1988)
suggesting that other factors are responsible for the MDR
phenotype in these cells. The present study investigates P-
glycoprotein gene amplification and expression in H69/LX4
(Twentyman et al., 1986) a second, independently derived
MDR variant of NCI-H69. We report that, in marked
contrast to H69/AR cells, amplification and hyperexpression
of P-glycoprotein gene occurs in this MDR cell line.
Materials and methods
Cell lines
The SCLC cell line NCI-H69 (kindly supplied by Drs
Desmond Carney and Adi Gazdar of the NCI Navy Medical
Oncology Branch, Bethesda, MD) was derived from a
patient who had previously received multidrug therapy
(including ADM).
Full details of the in vitro derivation of the MDR variant
of NCI-H69 are given elsewhere (Twentyman et al., 1986).
Briefly, NCI-H69 parent (H69P) cells were initially exposed
to 0.02pgml-1 ADM and then transferred to 0.04pgml-1
ADM after 3 weeks. After a further 4 weeks, ADM was
removed and when cell growth resumed, ADM was re-
introduced at weekly increasing doses of 0.1, 0.2 and
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0.4pgml-1- Cells growing well in 0.4pgml- were
designated H69/LX4 (LX4) and were found to have a
resistance factor for continuous growth of approximately
100. LX4 is also highly resistant to a number of drugs
including vincristine, colchicine and etoposide (Twentyman
et al., 1986).
H69P and LX4 were maintained in RPMI 1640 medium
supplemented with 10% fetal calf serum, penicillin and
streptomycin (all Gibco Europe Ltd).
The adenosine-, thymidine- and glycine-requiring auxo-
troph AUXB1 of Chinese hamster ovary (CHO) cells and its
colchicine-resistant mutant CH'CS (Juliano & Ling, 1976)
were kindly supplied by Dr Victor Ling of the Ontario
Cancer Institute, Toronto, Canada.
Antibodies to P-glycoprotein
The mouse monoclonal antibody C219 which recognises a
highly conserved determinant of P-glycoprotein (Kartner et
al., 1985) was generously donated by Dr Victor Ling.
cDNA probes
The mdrl-specific cDNA probe (pHDR105) (Roninson et
al., 1986) was generously donated by Dr Igor Roninson
(Center for Genetics, University of Illinois College of
Medicine at Chicago, Chicago). Identification of mdrl as a
human P-glycoprotein gene has been confirmed by cross-
hybridisation between P-glycoprotein and mdrl cDNA
clones (Ueda et al., 1986).
Preparation ofplasma membrane fractions
The isolation of plasma membranes was accomplished as
previously described (Riordan & Ling, 1979). Briefly, cells
were disrupted using a Stansted cell disruptor at a pressure
of 30p.s.i. for H69P and 20p.s.i. for LX4 cells. Following
differential centrifugation (Riordan & Ling, 1979) the
microsomal pellets were applied to a discontinuous sucrose
gradient consisting of 60% (w/v), 45%, 31% and 16%.
sucrose, and centrifuged at 76,900g for 18h. Material
banding at the three interfaces was collected and solubilised
in 0.1% sodium dodecyl sulphate (SDS). Protein
determinations were carried out using a BCA protein assay
kit (Pierce (UK) Ltd, Cambridge, UK).
Immunoblotting
For the immunodetection of P-glycoprotein, microsomal
membrane proteins were subjected to SDS-gel electrophoresis
(Debenham et al., 1982). Transfer of resolved proteins from
gels to nitrocellulose filter paper was as described by Towbin
et al. (1979). Protein transfer was performed for 4h at 4°C
at a constant current of 0.5A using a solution containing
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0.0125M Tris, 0.2M glycine (pH 8.5) and 20% methanol as
the electrode buffer. After transfer, additional protein
binding sites on nitrocellulose were blocked by incubation of
the paper overnight in 5mM EDTA, 0.25% gelatin, 0.01 M
NaN3, 0.15M NaCl, 0.05M Tris-base, and 0.05% Nonidet
P40 (NGA buffer). The paper was then incubated overnight
at 4°C with MoAb C219 diluted in NGA buffer. After
washing, 125I-labelled rabbit anti-mouse Ig was used to
visualise MoAb C219 binding.
RNA preparation
Cells in logarithmic phase of growth were collected by
centrifugation at 300g for 10min and suspended in 100l, of
medium. A solution containing 6.0 M guanidine hydro-
chloride and 0.2M sodium acetate (pH 5.5) was added to the
cells (20ml per 5 x 107 cells) and the DNA was sheared by
vigorous homogenisation in a Virtis homogeniser (Virtis
Company, New York). RNA was precipitated by the
addition of a half volume of 95% ethanol followed by
incubation at -20°C overnight. The pelleted precipitate was
dissolved in a solution containing 7.0M urea, 0.35M NaCI,
50mM Tris, pH 7.5, 1 mM EDTA and 0.2% SDS and was
extracted once with phenol-chloroform. RNA was
precipitated from the aqueous phase using 2 volumes of
ethanol, washed with 70% ethanol, air dried and dissolved in
sterile double distilled water.
Agarose gel electrophoresis
Twenty micrograms of total cellular RNA in 10mM sodium
phosphate buffer (pH 7.0) was denatured in 1.0 M glyoxal for
1 h at 50°C (Thomas, 1980). The RNA was then electro-
phoresed in a 1.4% agarose gel in 10mM sodium phosphate
buffer and was transferred by Northern blotting to nylon
filters (Thomas, 1980). After treatment for 2min with ultra-
violet light, the nylon filters were baked at 80°C for 2h
before hybridisation.
Preparation of radiolabelled probes
The mdrl cDNA probe was prepared by oligo-labelling
(Feinberg et al., 1984). The 2kb EcoRl fragment cloned into
the plasmid pHDR105 was separated from the vector by
agarose gel electrophoresis. The 2kb EcoRl fragment, still in
the gel slice, was radiolabelled by transcribing the fragment
using mixed oligonucleotides to initiate transcription. The
radiolabelled probe was separated from unincorporated
nucleotide triphosphates using Sephadex G50 (Pharmacia
Inc, Piscataway, NJ) and boiled for 3min before use. A
mouse ,B actin probe (PRT3) (kindly donated by Dr John
Rogers, Laboratory of Molecular Biology, Cambridge, UK)
was labelled by nick-translation (Rigby et al., 1977).
Hybridisation
The labelled probe, at a concentration of 106
counts min-1 ml-1, was hybridised to the filter in 1 M NaCl,
0.1 M trisodium citrate (6 x SSC), 5% dextran sulphate,
0.02% Ficoll, 0.02% bovine serum albumen, 0.02% poly-
vinyl pyrrolidone (Denhardt, 1966), 0.1% SDS and
150 pgml-1 sonicated salmon sperm DNA at 65°C for 18h.
The filter was washed with 6 x SSC, 0.1% SDS at 65°C to
remove unhybridised probe autoradiography.
DNA preparation and Southern blot analysis
DNA was prepared from cells in log phrase by lysis of the
cells in 0.3 M lithium acetate, 1 mM EDTA, 10mM Tris
pH 8.0, 2.0% lithium dodecyl sulphate. The lysate was then
subjected to three phenol-chloroform extractions and DNA
precipitated from the final aqueous phase with 0.2M sodium
acetate and 95% ethanol. Ten micrograms of DNA were
completely digested with Bgl II at 37°C and size fractionated
in 0.8% agarose gel. The DNA was denatured and trans-
ferred to nylon filter according to Southern (Southern, 1975).
Filters were treated with UV light for 2-5min. The oligo-
labelled mdrl cDNA probe at a concentration of 106
countsmin-1ml-I was hybridised to the filter as described
above. Filters were washed free of unhybridised probe with
0.1 x SSC, 0.1% SDS at 65°C and autoradiographed.
Results
Immunodetection of P-glycoprotein
Western blot analysis of microsomal membranes from H69P
and LX4 followed by immunoblotting with MoAb C219
demonstrated the presence of P-glycoprotein in the CHRC5
cell line and LX4 subline but not in H69P (Figure 1). A
trace amount of P-glycoprotein was detected with this anti-
body in AUXBI as previously reported by others (Kartner et
al., 1985).
Detection of P-glycoprotein mRNA
The hybridisation pattern ofthe mdrl probe to RNA from the
cell lines H69P and LX4 is shown in Figure 2a. The probe
hybridised to RNA from LX4 only. The same filter as was
used for the mdrl probe was also probed for the presence
of actin mRNA with a plasmid probe to confirm that the
H69P cell line track contained approximately the same
amount of total RNA as the LX4 track. Figure 2b indicates
that the actin probe hybridised to RNA in both tracks and
confirms that the lack of signal with the mdrl probe in the
lane containing H69P RNA is due to undetectable levels of
mrdl RNA in the parent line.
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Figure 1 Immunodetection of P-glycoprotein in H69P, LX4,
AUXB1 and CHRCS by monoclonal antibody C219 following
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Figure 3 P-glycoprotein gene amplification in LX4 cells.
Southern blot analysis of DNA hybridised with the mdrl specific
cDNA probe. Visual inspection of ethidium bromide stained gels
showed that approximately equal amounts of DNA were loaded
onto agarose gels before Southern blotting.
Figure 2 a, Expression of mdrl sequences in LX4 and H69P
cells. Northern blot of RNA hybridised with the mdrl specific
probe, pHDR105. The size of the RNA transcript homologous
to the cDNA probe is approximately 5kb. b, Actin mRNA levels
in total RNA extracted from LX4 and H69P cells, as used in a,
detected by the pRT3 probe for mouse actin. The size of the
RNA transcript homologous to the probe is 1.8kb.
P-glycoprotein gene amplification
Southern filter hybridisation analysis of P-glycoprotein gene
amplification in H69P and LX4 is shown in Figure 3.
Amplification of the P-glycoprotein gene is observed in
LX4 only.
Discussion
Good evidence supports an aetiological role for P-
glycoprotein in MDR in almost all cell lines studied.
However, amplification and expression of the P-glycoprotein
gene in LX4 is particularly notable in view of an earlier
report (Mirski et al., 1987; Trent et al., 1988) which failed to
demonstrate amplification, rearrangement or expression of
the P-glycoprotein gene in a similar MDR variant of NCI-
H69, designated H69/AR. This MDR subline was also
selected for resistance to ADM, exhibits approximately the
same degree of resistance to ADM as LX4, and like LX4 is
cross-resistant to vincristine, colchicine and etoposide, but
not to bleomycin. While the pCHPl probe (Riordan et al.,
1985) was used to detect P-glycoprotein gene amplification
and expression in H69/AR and mdrl specific cDNA probe
(pHDR105) was used in the present study, both investi-
gations utilised the monoclonal antibody C219, which detects
a highly conserved determinant of P-glycoprotein. This
antibody, while reacting with LX4, failed to detect P-
glycoprotein in H69/AR (Mirski et al., 1987; Trent et al.,
1988). Hence, our findings and those previously reported for
H69/AR (Mirksi et al., 1987; Trent et al., 1988) indicate that
a single selecting agent can generate MDR variants from a
single cell line, which have similar degrees of MDR, but
which may or may not express P-glycoprotein. The nature of
the cellular changes reponsible for the MDR phenotype in
cells not expressing P-glycoprotein (i.e. H69/AR) remain to
be elucidated. However, it is apparent that the NCI-H69 cell
line has at least two alternative biochemical pathways which
lead to MDR: one involving P-glycoprotein, the other not.
This is further supported by the observed differences in the
efficacy of verapamil (VRP) to overcome MDR in H69/AR
and LX4. Only drug resistance associated with P-
glycoprotein has been shown to be susceptible to reversal by
VRP and for LX4 a clear dose-dependent enhancement of
ADM sensitivity by VRP has been demonstrated
(Twentyman et al., 1986). However, for H69/AR, verapamil
enhanced ADM cytotoxicity only slightly and the effect was
not dose-dependent (Cole et al., 1989). NCI-H69 shows a
LX4 H69P
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heterogenous cytology, being a mixture of intermediate and
large cell types (A.F. Gazdar, personal communication).
Whether the expression of alternative mechanisms of MDR
by NCI-H69 reflects the intrinsic properties of different cell
types within the line, or whether a single cell type possesses
multiple mechanisms of drug resistance, remains to be
elucidated.
The findings of the present study show that the MDR
SCLC tumour cells in vitro are able to elaborate a MDR
phenotype involving P-glycoprotein and raise the possibility
that P-glycoprotein hyperexpression is a clinically relevant
component of MDR in some SCLC tumours. However, to
date studies of mdrl gene expression in SCLC cell lines from
drug-treated patients have found no evidence that this is the
case (A.F. Gazdar, personal communication).
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